9 Results for "

CD4 Foxp3

" in MedChemExpress (MCE) Product Catalog:
Products (9)

9 Results for "CD4 Foxp3" in MCE Product Catalog:

6
6 Publications Verification
Cat. No.: HY-126675A
CAS No.: 2241300-51-4
Purity:  99.94%
Research Areas:  

Inflammation/Immunology

AS2863619 is an orally active CDK8/19 inhibitor that also inhibits BMP2, MDA5 and RIG-I receptors. AS2863619 targets Stat5a-CDK8/19 to promote the differentiation of CD4 + T cells into regulatory T cells and induce FOXP3 expression, thereby restoring immune homeostasis and establishing transplant immune tolerance. AS2863619 also enhances the BMP2/SMAD signaling pathway to promote osteogenic differentiation and inhibit adipogenic differentiation. AS2863619 exerts osteoprotective effects by alleviating inflammation-induced impairment of osteogenic function and inducing neutrophil apoptosis (apoptosis). AS2863619 can be applied to research in related fields such as periodontitis-induced bone defects [3].
loading...
    loading...
6
6 Publications Verification
Cat. No.: HY-126675
CAS No.: 2241300-50-3
Purity:  99.68%
Research Areas:  

Inflammation/Immunology

AS2863619 free base is an orally active CDK8/19 inhibitor that also inhibits BMP2, MDA5 and RIG-I receptors. AS2863619 free base targets Stat5a-CDK8/19 to promote the differentiation of CD4 + T cells into regulatory T cells and induce FOXP3 expression, thereby restoring immune homeostasis and establishing transplant immune tolerance. AS2863619 free base also enhances the BMP2/SMAD signaling pathway to promote osteogenic differentiation and inhibit adipogenic differentiation. AS2863619 free base exerts osteoprotective effects by alleviating inflammation-induced impairment of osteogenic function and inducing neutrophil apoptosis (apoptosis). AS2863619 free base can be applied to research in related fields such as periodontitis-induced bone defects [3].
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P1684
CAS No.: 1319725-20-6
Synonyms: Foxp3 inhibitor P60
Peptide P60 is a FOXP3 inhibitor. Peptide P60 reduces the nuclear translocation of FOXP3 and impairs FOXP3-mediated inhibition of NF-κB and NFAT activity. Peptide P60 inhibits the immunosuppressive activity of regulatory T cells and restores the proliferation and activation of effector T cells. Peptide P60 induces lymphoproliferative autoimmune syndrome in neonatal ICR mice and reduces the number of CD4 +CD25 +Foxp3 + T cells in the spleen. Peptide P60 enhances the efficacy of AH1 (HY-P4193) peptide vaccine and recombinant adenovirus-based HCV NS3 vaccine in BALB/c mice, including protective effects against CT26 tumor implantation. Peptide P60 can be used in studies related to tumor immunity, viral infection and lymphoproliferative autoimmune syndrome .
loading...
    loading...
Cat. No.: HY-148808
CAS No.: 2365193-22-0
Purity:  99.33%
Synonyms: RXC007
Target:  

ROCK

Research Areas:  

Cancer

Zelasudil (RXC007) is an orally active, highly selective small molecule Rho-associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor with anti-fibrotic efficacy. Zelasudil elicits positive immunomodulatory effects in metastatic pancreatic tumors with increase of CD8+ and CD4+ T cell infiltrate into the tumor cortex and reduction in immunosuppressive FOXP3+ regulatory T cells at the tumor border. Zelasudil is promising for research of pancreatic ductal adenocarcinoma [3] [4].
loading...
    loading...
Cat. No.: HY-W060417
CAS No.: 1019158-02-1
Target:  

Interleukin Related

Research Areas:  

Inflammation/Immunology Cancer

iST2-1 is an Stimulation-2 (ST2) inhibitor with an IC50 value of 46.65 μM, blocks interaction between ST2 and IL-33, inhibits downstream signaling. iST2-1 functions as an immunomodulator, reduces proliferation of CD4 + and CD8 + T cells, increases regulatory T cell populations, reduces IFN-γ +CD4 + T cell populations, increases Foxp3 +CD4 + regulatory T cell populations in the gastrointestinal tract. iST2-1 reduces plasma soluble ST2 and IFN-γ levels, reduces graft-versus-host disease scores, improves survival in graft-versus-host disease animal models, preserves graft-versus-tumor effect. iST2-1 can be used for the research of graft-versus-host disease .
loading...
    loading...
Cat. No.: HY-15091
CAS No.: 170368-04-4
Synonyms: LF-150195
Target:  

Endogenous Metabolite

Research Areas:  

Neurological Disease

Anisperimus (LF-150195) is an immunosuppressant with the activity of enhancing activation-induced T cell death. Anisperimus enhances the sensitivity of T cells to anti-CD95 antibodies and other inducers by promoting the activation of caspase-8 and caspase-10 at the level of the death-inducing signaling complex (DISC). Anisperimus also promotes the development of Foxp3-expressing regulatory CD4 T cells, thereby preventing central nervous system autoimmunity .
loading...
    loading...
Cat. No.: HY-P991824

Research Areas:  

Inflammation/Immunology

Anti-Mouse CD4 Antibody (YTS 177) reacts with the mouse CD4. Anti-Mouse CD4 Antibody (YTS 177) shows non-depleting but binding does induce rapid internalization of CD4 on both CD4 + Foxp3- T cells and Foxp3 + regulatory T cells. Recommend Isotype Controls: Rat IgG2a kappa, Isotype Control (HY-P990679) .
loading...
    loading...
Cat. No.: HY-N20707
CAS No.: 24312-00-3
Castalagin is an orally active natural product with multiple biological activities including antibacterial activity against bacteria and anti-leishmanial activity against Leishmania aethiopica. Castalagin exhibits inhibitory activity against PARP1 and DNA topoisomerase II, with an IC50 of 0.86 μM for bovine PARP1. Castalagin reduces poly (ADP-ribosyl) ation modification in cells. Castalagin binds to the cell envelope of Ruminococcus bromii, increases the ratio of CD8+/FOXP3+CD4+ T cells in the tumor microenvironment, and acts as a prebiotic to enhance the activity of anti-PD-1 therapy. Castalagin induces morphological changes in Leishmania aethiopica promastigotes and inhibits their proliferation. Castalagin inhibits PBP2a-mediated peptidoglycan layer stabilization, disrupts bacterial peptidoglycan assembly, and inhibits and disintegrates bacterial biofilms. Castalagin can be used in research related to diseases such as cancer, leishmaniasis, and bacterial infections [3] [4].
loading...
    loading...
Cat. No.: HY-126675G
CAS No.: 2241300-51-4
AS2863619 GMP is AS2863619 (HY-126675) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. AS2863619 is an orally active CDK8/19 inhibitor that also inhibits BMP2, MDA5 and RIG-I receptors. AS2863619 targets Stat5a-CDK8/19 to promote the differentiation of CD4 + T cells into regulatory T cells and induce FOXP3 expression, thereby restoring immune homeostasis and establishing transplant immune tolerance. AS2863619 also enhances the BMP2/SMAD signaling pathway to promote osteogenic differentiation and inhibit adipogenic differentiation. AS2863619 exerts osteoprotective effects by alleviating inflammation-induced impairment of osteogenic function and inducing neutrophil apoptosis (apoptosis). AS2863619 can be applied to research in related fields such as periodontitis-induced bone defects [3].
loading...
    loading...